Dimensional Fund Advisors LP Increases Position in Bioventus Inc. $BVS

Key Points

• Dimensional Fund Advisors increased its Bioventus stake by 14.1% in the first quarter, bringing its holdings to 873,138 shares valued at approximately $7.97 million. Institutional investors collectively own 62.94% of BVS.
• Analysts remain positive on Bioventus, with a consensus “Buy” rating and an average price target of $16.25; individual targets range from $15 to $18.
• Bioventus reported quarterly EPS of $0.22, matching estimates, on revenue of $153.21 million. The company issued fiscal 2026 EPS guidance of $0.75–$0.79, while shares recently traded at $13.96.

Dimensional Fund Advisors LP grew its holdings in shares of Bioventus Inc. (NASDAQ:BVS - Free Report) by 14.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 873,138 shares of the company's stock after purchasing an additional 107,930 shares during the period. Dimensional Fund Advisors LP owned approximately 1.05% of Bioventus worth $7,971,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BVS. Marshall Wace LLP raised its stake in Bioventus by 0.4% during the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company's stock valued at $2,149,000 after buying an additional 1,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company's stock valued at $211,000 after acquiring an additional 1,538 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Bioventus by 16.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company's stock worth $101,000 after purchasing an additional 1,887 shares during the last quarter. Deutsche Bank AG boosted its stake in Bioventus by 8.2% in the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company's stock worth $187,000 after purchasing an additional 1,908 shares in the last quarter. Finally, Engineers Gate Manager LP grew its position in Bioventus by 6.0% during the 4th quarter. Engineers Gate Manager LP now owns 68,889 shares of the company's stock valued at $513,000 after purchasing an additional 3,909 shares during the last quarter. Institutional investors own 62.94% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Barrington Research set a $18.00 target price on shares of Bioventus in a research note on Thursday. Canaccord Genuity Group reiterated a "buy" rating and set a $15.00 target price on shares of Bioventus in a research note on Tuesday, June 16th. Craig Hallum restated a "buy" rating and issued a $18.00 price target on shares of Bioventus in a research note on Thursday. Finally, Weiss Ratings raised Bioventus from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Bioventus currently has a consensus rating of "Buy" and an average target price of $16.25.

Bioventus Stock Performance

BVS opened at $13.96 on Tuesday. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. The company has a market cap of $1.17 billion, a price-to-earnings ratio of 18.13, a PEG ratio of 1.80 and a beta of 0.63. The company's 50 day moving average is $10.93 and its 200 day moving average is $9.74. Bioventus Inc. has a 12-month low of $6.26 and a 12-month high of $15.89.

Bioventus (NASDAQ:BVS - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.22 EPS for the quarter, meeting analysts' consensus estimates of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The business had revenue of $153.21 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities research analysts predict that Bioventus Inc. will post 0.79 EPS for the current year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source